Scientists in India are looking to further widen their footprint in drug delivery manufacturing, getting in on one of the early floors of a promising technology in the field: nanocrystals. And the researchers say their method is more advanced than that of the small number of countries also involved in the burgeoning arena, giving them what could be a leg up as crystallization becomes a marketable platform.
"Cover all the bases" is the theme of FierceDrugDelivery's annual list of the top drug delivery partnerships. Finding 10 significant alliances that represent the full range of drug delivery advances was a challenge, and there are certainly other deals out there that are both novel and of high importance.
Still, the tie-ups highlighted here represent the arena's diversity on multiple levels. Half of the deals involve use of drug delivery devices like "smart" inhalers and drug-coated angioplasty balloons, while others focus on the molecular aspects, like transportation across biological barriers and the development of formulations that are efficacious and/or differentiate the medication.
We considered deals that commenced in 2014 and so far in 2015.
Cambridge, MA's Ra Pharma received $58.5 million from a mix of strategic and VC investors to take on Alexion's intravenously infused orphan drug Soliris with a cheaper, subcutaneously delivered alternative. Its preclinical peptide-inhibiting candidate aims to shake up the paroxysmal nocturnal hemoglobinuria market using an alternative form of drug delivery. Read more >>
POPULAR COMMENT THREADS
A former Unilife employee apologized to the company for falsely accusing the company of misleading investors in press releases, and agreed to make payments to settle a countersuit filed against him following his failed whistleblower lawsuit.
Australia's RNA interference specialist Benitec Biopharma chose a bad week to debut on the Nasdaq. The company raised $14 million by offering 1.5 million American depositary shares on Aug. 18, but its stock was down 13% by Friday, a week which saw the Nasdaq Biotechnology Index fall 4.5%.
A new copper-based biological nanomaterial discovered and assembled at Louisiana Tech University interacts with cells in the body and could ultimately be used as a targeted delivery tool to treat cancer and other diseases.
In November the federal National Science Foundation awarded a $700,000 research grant to Hospi so that it could expand use of the only FDA-cleared device for rectal delivery of medications. The early results look promising.
Matinas BioPharma's lead antifungal candidate (MAT2203) earned the FDA's fast track designation as a so-called Qualified Infectious Disease Product, demonstrating the agency's efforts to speed along medications for infectious diseases after years of industry under-investment in that arena.
Edge Therapeutics is deploying drug delivery to improve the standard of care for treating ruptured brain aneurysms, and hopes to receive $115 million via an IPO on the Nasdaq, for which it just filed.
From Our Sister Sites
Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.
Engineer Scott Leibrand and diabetes patient Dana Lewis have created an artificial pancreas, via years of constant experimentation and iterative upgrades.